Karen S L Lam, Chun Chung Chow, Kathryn C B Tan, Ronald C W Ma, Alice P S Kong, Peter C Y Tong, Man Wo Tsang, Tak Mao Chan, Sydney C W Tang, Ka Kui Lee, Wing Yee So, Brian Tomlinson
Sodium-glucose co-transporter type 2 (SGLT2) inhibitors are a new class of oral anti-diabetic agents with a unique, insulin-independent mode of action. In patients with diabetes who have adequate renal function, SGLT2 inhibitors reduce hyperglycemia by blocking renal glucose reabsorption and increasing urinary glucose excretion. These agents are indicated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM), as an adjunct to diet and exercise. In terms of efficacy, they are comparable to most other oral agents, and carry a low risk of hypoglycemia unless combined with sulfonylureas or insulin...
June 2016: Current Medical Research and Opinion